Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 860 participants.

Also called NCT03496883

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 860 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03496883
  • EudraCT 2019-003722-25
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, Japan, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03496883. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-03 (actual); primary completion 2028-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Acronym
FASTEST
Condition
Intracerebral Hemorrhage
Intervention (Biological)
Recombinant Activated Factor VII (rFVIIa)
Intervention (Biological)
Placebo
Lead sponsor
Joseph Broderick, MD (class: other)
Collaborator
Novo Nordisk A/S (class: industry)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03496883
Content hash
78010e774da590b2f305c9261b9b7efe2903146d4846389c4472038bfe5d59a8